From GlobeNewswire: 2025-05-07 08:00:00

Barinthus Bio announced Phase 1 single ascending dose data for celiac disease treatment expected in Q3 2025, with Phase 1 multiple ascending dose initiation later in 2025. Positive results from HBV003 and IM-PROVE II trials presented at EASL support partnering efforts. Resources expected to last until 2027. Financial results for Q1 2025 show a cash balance of $100.6 million. Research and development expenses decreased to $8.3 million from $11.1 million in Q1 2024. General and administrative expenses increased to $12.6 million in Q1 2025. Net loss for Q1 2025 was $19.6 million. Barinthus Bio focuses on immunology and inflammation diseases. Their lead candidate, VTP-1000, is in a Phase 1 clinical trial for celiac disease. They use a proprietary platform, SNAP-TI, to develop immune tolerance therapies. The company aims to deliver potentially curative treatments for autoimmune and inflammatory diseases. The company’s consolidated balance sheet as of March 31, 2025, shows total assets of $141.996 million and total liabilities of $26.403 million. The company’s consolidated statement of operations and comprehensive loss for Q1 2025 shows a net loss of $19.658 million. Contact information for investors and media is provided.



Read more at GlobeNewswire:: Barinthus Bio Reports First Quarter 2025 Financial Results